DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the business’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $84.41, for a total value of $300,499.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
John Lister also recently made the following trade(s):
- On Friday, September 9th, John Lister sold 3,560 shares of DexCom stock. The shares were sold at an average price of $93.65, for a total value of $333,394.00.
DexCom Inc. (NASDAQ:DXCM) opened at 81.98 on Friday. DexCom Inc. has a 12 month low of $47.92 and a 12 month high of $96.38. The stock’s market cap is $6.88 billion. The firm’s 50 day moving average price is $89.90 and its 200 day moving average price is $78.39.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The firm had revenue of $137.30 million for the quarter, compared to analysts’ expectations of $132.48 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The company’s revenue was up 47.3% compared to the same quarter last year. On average, equities research analysts predict that DexCom Inc. will post ($0.57) EPS for the current fiscal year.
DXCM has been the topic of several research analyst reports. JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a research report on Monday, June 20th. Zacks Investment Research downgraded DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Canaccord Genuity restated a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research report on Wednesday, July 13th. Jefferies Group reaffirmed a “buy” rating and issued a $98.00 target price (up from $90.00) on shares of DexCom in a report on Friday, July 15th. Finally, Deutsche Bank AG lifted their target price on DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, July 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $95.08.
A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. BNP Paribas Arbitrage SA raised its position in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares in the last quarter. Bellwether Investment Group LLC bought a new position in shares of DexCom during the second quarter worth $119,000. Bank of Montreal Can bought a new position in shares of DexCom during the second quarter worth $134,000. Capstone Asset Management Co. bought a new position in shares of DexCom during the third quarter worth $205,000. Finally, Private Bank & Trust Co. bought a new position in shares of DexCom during the third quarter worth $220,000. 99.37% of the stock is currently owned by hedge funds and other institutional investors.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.